Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amgen and Cytokinetics heart failure drug shows positive result in phase 2 trial
In the expansion phase of the trial, 448 patients were given an oral formulation of the omecamtiv mecarbil drug for 20 weeks and observed for 24 weeks. Patients
In the expansion phase of the trial, 448 patients were given an oral formulation of the omecamtiv mecarbil drug for 20 weeks and observed for 24 weeks. Patients
The company said patients taking the FDA-approved 2 milligram dosage of Keytruda and those taking an experimental 10 milligram dose had longer overall survival compared with those taking
The company is using its True Human technology for the program. It has started screening human blood samples from donors to detect and clone a therapeutic antibody candidate
Ipsen is developing a new platform of novel neurotoxin derived therapeutics, including TSI, to create new therapeutic opportunities for addressing several medical conditions with unmet requirements. The program
Under the four-year research collaboration, the companies will evaluate the use of CRISPR-Cas9 DNA gene editing technology to address mutations and genes that cause or contribute to cystic
The deal grants Kite an exclusive global license to research, develop and commercialize engineered autologous T cell therapies incorporating two programs from Alpine’s transmembrane immunomodulatory protein (TIP) technology.
The technology provides targeted release of gastric acid- and heat-sensitive active ingredients to the upper gastrointestinal tract. It allows oral delivery of several compounds, including vaccines, proteins and
Under the deal, Glenmark has obtained semi-exclusive marketing and distribution rights of the product across 15 European countries including the UK, Germany, Belgium, the Netherlands, Italy, Sweden, Norway,
ondelis is approved for patients with two forms of STS, liposarcoma or leiomyosarcoma, who had earlier received chemotherapy that contained anthracycline. While it is approved for both leiomyosarcoma
The company received a complete response letter, which the FDA sends to a company to inform that the marketing application will not be approved in its existing form.